Bezafibrat

Bezafibrat
Klinički podaci
Prodajno ime	Befizal, Bezalip, Bezalip retard, Bezatol
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	1-2 h
Identifikatori
CAS broj	41859-67-0
ATC kod	C10AB02 (WHO)
PubChem	CID 39042
IUPHAR/BPS	2668
DrugBank	DB01393
ChemSpider	35728
ChEBI	CHEBI:47612
ChEMBL	CHEMBL264374
Hemijski podaci
Formula	C19H20ClNO4
Molarna masa	361,819
	SMILES CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O; ;
	InChI InChI=1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24) ; Key:IIBYAHWJQTYFKB-UHFFFAOYSA-N ;
Fizički podaci
Tačka topljenja	186 °C (367 °F)

Bezafibrat je organsko jedinjenje, koje sadrži 19 atoma ugljenika i ima molekulsku masu od 361,819 Da.^[1]^[2]^[3]^[4]^[5]^[6]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	4
Broj donora vodonika	2
Broj rotacionih veza	7
Particioni koeficijent^[7] (ALogP)	3,9
Rastvorljivost^[8] (logS, log(mol/L))	-5,9
Polarna površina^[9] (PSA, Å²)	75,6

Reference

^ Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. . „the Bezafibrate Infarction Prevention (BIP) study”. Circulation. 102 (1): 21—7. 2000 Jul 4. PMID 10880410. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. . „Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome”. Arch Intern Med. 165 (10): 1154—60. 2005 May 23. PMID 15911729. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S. . „Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease”. Circulation. 109 (18): 2197—202. 2004 May 11. PMID 15123532. Проверите вредност парамет(а)ра за датум: |date= (помоћ) May 3.
^ Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, Behar S. . „Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate”. Arch Intern Med. 166 (7): 737—41. 2006 Apr 10. PMID 16606809. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). . „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). . „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). . „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). . „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). . „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Bezafibrate

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. . „the Bezafibrate Infarction Prevention (BIP) study”. Circulation. 102 (1): 21—7. 2000 Jul 4. PMID 10880410. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[2] Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. . „Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome”. Arch Intern Med. 165 (10): 1154—60. 2005 May 23. PMID 15911729. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[3] Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S. . „Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease”. Circulation. 109 (18): 2197—202. 2004 May 11. PMID 15123532. Проверите вредност парамет(а)ра за датум: |date= (помоћ) May 3.

[4] Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, Behar S. . „Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate”. Arch Intern Med. 166 (7): 737—41. 2006 Apr 10. PMID 16606809. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[5] Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). . „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[6] Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). . „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[7] Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). . „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.

[8] Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). . „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[9] Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). . „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]